Recombinant human interleukin-2（3SBio）

重组人白介素-2 (沈阳三生制药）

Report date: 2022/01/14 13:23:58

Base Information

Drug NameRecombinant human interleukin-2（3SBio）
Drug Alias Name英路因inleusin
ClassificationBiologics > Protein drugs > Recombinant protein > Recombinant cytokines
Mechanisms of ActionInterleukin-2 receptor agonists
TargetsInterleukin-2 receptor
Therapy Area/IndicationsPleural Effusion, MalignantCarcinoma, Renal CellMelanoma +[4] 
Global Approved IndicationsPleural Effusion, MalignantCarcinoma, Renal CellMelanoma +[4] 
Approved Indications in ChinaPleural Effusion, MalignantCarcinoma, Renal CellMelanoma +[4] 
Original Approved Country/TerritoryMainland China
Original Approved Date1997/01/01
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesShenyang Sunshine Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesShenyang Sunshine Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsPleural Effusion, MalignantCarcinoma, Renal CellMelanoma +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeL03AC01
Related LinksN/A